Vor Biopharma (VOR) shares were down 1.2% in Tuesday trading after the company reported its Q2 results.
The company reported a Q2 net loss of $1.16 per diluted share, narrower than a loss of $251.24 a year earlier.
Analysts polled by FactSet expected a loss $0.70.
As of June 30, the company said it had $466.1 million in cash, cash equivalents and marketable securities, which it expects to fund operations through early 2029 taking into account $48.4 million net proceeds from at-the-market sales during July.
Price: $23.13, Change: $-0.24, Percent Change: -1.03%